SCHEMBL20738604

SCHEMBL20738604

CC(=O)N1CCc2cccc(C(F)(F)F)c2C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 4/20 0.56
PHGDH O43175 1/20 0.52
DRD2 P14416 1/20 0.47
ACKR3 P25106 1/20 0.46
ABHD6 Q9BV23 1/20 0.46
BRD4 O60885 2/20 0.44
CREBBP Q92793 2/20 0.44
EP300 Q09472 1/20 0.44
RBP4 P02753 2/20 0.44
ACACB O00763 1/20 0.43
ALDH1A1 P00352 1/20 0.43
PKM P14618 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
BAZ2B Q9UIF8 1/20 0.43
SCN9A Q15858 1/20 0.42
EGFR P00533 2/20 0.41
PTAFR P25105 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2930889 0.87 PHGDH (0.50) NOTUMPHGDHDRD2ABHD6RBP4
SCHEMBL3885156 0.86 ESR1 (0.51) NOTUMPHGDHDRD2ACKR3ABHD6
SCHEMBL24925779 0.85 PHGDH (0.49) NOTUMPHGDHDRD2ACKR3ABHD6
SCHEMBL20389165 0.83 ESR2 (0.52) NOTUMPHGDHDRD2ABHD6SCN9A
SCHEMBL11737534 0.81 NOTUM (0.47) NOTUMBRD4CREBBPEP300RBP4
SCHEMBL14591318 0.80 NOTUM (0.65) NOTUMBRD4CREBBPEP300ALDH1A1
SCHEMBL17197242 0.79 NOTUM (0.63) NOTUMDRD2ABHD6BRD4CREBBP
SCHEMBL12269322 0.78 NOTUM (0.61) NOTUMDRD2ABHD6BRD4CREBBP
SCHEMBL2252826 0.78 NOTUM (0.61) NOTUMABHD6BRD4CREBBPEP300
SCHEMBL9270908 0.78 NOTUM (0.61) NOTUMDRD2ALDH1A1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 US disclosed
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-05-11 US disclosed
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-10-29 US disclosed
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 NOTUM 4102/4885PHGDH 3159/4885DRD2 3577/4885
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 NOTUM 4102/4885PHGDH 3159/4885DRD2 3577/4885
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 NOTUM 4156/4885PHGDH 3166/4885DRD2 3466/4885
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 NOTUM 4102/4885PHGDH 3159/4885DRD2 3577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.